Olmesartan helps Daiichi Sankyo back into the black
This article was originally published in Scrip
Executive Summary
Continued good growth for the antihypertensive olmesartan was behind a 13% increase in Daiichi Sankyo's net sales in the year to 31 March, to ¥952.1 billion ($10.24 billion).